AIIMS in Delhi begins the screening of children for clinical trials of Covaxin today, clinical trials of Bharat Biotech’s Covaxin will be conducted to see it is suitable for children between the age of two and 18 years by All India Institute of Medical Science (AIIMS) in the national capital after similar trials initiated by AIIMS in Patna according to the Sources.
Children could become a prime target of the third wave as it could bring a similar devastation as the second wave therefore it is essential to vaccinate enough people in order to deal with it, as cautioned by experts. The centre had given the clearance for clinical trials on 13th May to be conducted on the children of age group two to 18 years as said by a senior NITI Aayog member, Dr. VK Paul last month.
The vaccine made by Pfizer-BioNTech’s have been authorised by Canada and the United States for use in certain age groups of children. Vaccine made by Chinese firm Sinovac, CoronaVac has been approved for an emergency use on children aged between 3 and 17 years. Covid wave is though receding thereby normalising the situation, India had reported around 4 lakh daily cases in April was logged 1.14 lakh fresh cases on Saturday which is the lowest in two months.
The health infrastructure was brought to the urge of collapsing due to the death of hundreds of people because of the second wave of Covid-19 pandemic. A lot of deaths also occurred due to the lack of medical grade oxygen and hospital beds.